Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activated protein kinases and G2-phase cell cycle arrest

• Published in: Life sciences (1973) Vol. 72; no. 21; pp. 2381 - 2390
• Main Authors: Lin, Shwu-Bin, Li, Chyi-Hann, Lee, Shiuh-Sheng, Kan, Lou-Sing
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 11.04.2003
• Subjects: Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - enzymology; Chemical Fractionation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal - chemistry; Drugs, Chinese Herbal - pharmacology; G. lucidum; G2 Phase - drug effects; Liver Neoplasms - drug therapy; Liver Neoplasms - enzymology; MAP kinases; Mitogen-Activated Protein Kinases - biosynthesis; p38 Mitogen-Activated Protein Kinases; PKC; Protein Kinase C - antagonists & inhibitors; Protein Kinase C - metabolism; Reishi - chemistry; Triterpenes; Triterpenes - pharmacology; Tumor Cells, Cultured - drug effects; Tumor Cells, Cultured - enzymology; Tumorcidal; G. lucidum; Triterpenes; PKC; Tumorcidal; MAP kinases

The medicinal mushroom Ganoderma lucidum (G. lucidum) has been used in the Orient for the prevention and treatment of various diseases including cancer. Except for the immune enhancing properties of its polysaccharide constituent, very little is known about the anticancer activity of another major c...